{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-196671","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2022-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.812621+00:00","generated_at":"2026-06-24T11:59:52.519028+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"INOVIO cuts 18% workforce (55 employees) and 86% of contractors to extend cash runway to Q3 2024","bullets":["Headcount reduced by 55 employees (18% of full-time staff) and 86% of contractor agreements terminated.","Expected to reduce operating expenses by ~30% over 18 months; cash runway extended into Q3 2024.","One-time pre-tax charge of $1.6 million in Q3 2022; cash payments substantially completed by Sept 30, 2022.","Focus shifts to heterologous boost strategy for COVID-19 vaccine (INO-4800) and HPV programs; key data readouts later in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-196671","json":"https://secwatch.observer/filing/0001193125-22-196671.json","markdown":"https://secwatch.observer/filing/0001193125-22-196671.md","text":"https://secwatch.observer/filing/0001193125-22-196671.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000119312522196671/0001193125-22-196671-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000119312522196671/d382508d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T11:59:52.519028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}